AZ-BLUE-YONDER
Blue Yonder, a leader in digital supply chain transformations, continues its forward momentum to revolutionize the supply chain and has today announced the signing of an agreement to acquire One Network Enterprises (One Network) for approximately $839 million, subject to adjustments. One Network, provider of the Digital Supply Chain Network™, is known for its autonomous and resilience services and is a leading global provider of intelligent control towers. Upon completion, Blue Yonder will be well positioned to serve customers’ needs across planning, execution, commerce, and networks.
“Supply chains have become more complex, and as more and more companies reduce risk by diversifying sourcing of products globally, there is an increased demand for the sharing of information and resources across the whole value chain. This, along with increased disruptions and geopolitical risks, have put the pressure on organizations to build more resilient and robust supply chains,” said Duncan Angove, CEO, Blue Yonder. “Combined with One Network’s capabilities, Blue Yonder will establish itself as a leading supply chain solutions company that can offer a unified, end-to-end supply chain ecosystem that is resilient enough to withstand today’s challenges, and synthesized with innovative, future-focused technologies.”
The combination of One Network’s Digital Supply Chain Network™ and Blue Yonder’s supply chain capabilities create an ecosystem that:
- Offers real-time, multi-enterprise optimization, orchestration, and collaboration both inside and outside an organization – across multi-tiers from customers to carriers to suppliers to the suppliers’ suppliers.
- Allows customers to move from the order planning phase to the fulfillment phase instantly, eliminating the time gap that normally occurs from entering the order to beginning the physical fulfillment. Customers can also tap into a more complete and actionable data set across the multi-enterprise ecosystem by setting up alerts, benefiting from automation, and leveraging generative artificial intelligence (AI).
- Provides real-time visibility across the supply chain, allowing customers to take immediate action via upstream and downstream collaboration.
- Unifies disparate data silos, enabling a holistic, executive-level view into the entire supply chain – resulting in the ability to automatically optimize and execute through prescriptive real-time decision-making technology.
In addition, carriers and suppliers will be able to leverage a range of services designed specifically for their needs, including: advanced shipment scheduling management, telematics tracking and predictive insights, real-time visibility to on-time delivery trends (by site, lane, carrier, distribution center), and the ability to manage by exception.
“Supply chains continue to be fragmented and overwhelmed with disruptions. What’s needed is a unified platform that enables multi-tier orchestration, planning, and collaboration that accelerates processes with autonomous and semi-autonomous decision-making and execution across trading partners. This is the next step to creating a resilient and collaborative supply chain,” said Greg Brady, chairman and founder, One Network. “Blue Yonder offers the most complete portfolio in the industry, spanning from planning to execution. Coupled with our network and multi-enterprise, multi-tier platform, we’re poised to form a backbone of this new supply chain of the future.”
By tapping into One Network’s revolutionary platform and multi-party network, leveraged by over 150,000 trading partners, Blue Yonder’s customers will benefit from an ecosystem that:
- Accelerates end-to-end decision-making, with increased visibility into materials, resources, loads, routes, and capacity.
- Offers real-time insights and predictions, enabling the ability to take action across the supply chain ecosystem, leading to fewer disruptions and a more resilient supply chain.
- Shares data seamlessly across the entire multi-tier supply chain, including suppliers and carriers, allowing for streamlined insights into potential disruptions and the ability to mitigate risk.
- Improves supplier and carrier collaboration processes – from order creation through scheduling and fulfillment – from days to minutes, removing inaccuracies, reducing time, and decreasing cost.
- Enables the journey to autonomous supply chain management through Smart Prescriptions™, adaptive flows, and interactive visualizations, powered by proprietary AI technology.
The closing of the transaction is subject to the satisfaction of customary conditions precedent in transactions of this type, including necessary regulatory approvals, and is expected to occur in Q2 or Q3 2024. This deal is indicative of Blue Yonder's momentum in the supply chain management space, and when completed, will mark approximately $1 billion in M&A investments covering three acquisitions since Q4 2023. This announcement comes on the heels of Blue Yonder’s acquisition of flexis, offering factory planning, sequencing, and slotting capabilities, and Doddle, offering returns management and reverse logistics solutions.
About One Network Enterprises
One Network Enterprises (ONE) is a leading global provider of intelligent control towers and the Digital Supply Chain Network™. Its solutions give supply chain managers and executives end-to-end visibility and control with one data model and one truth, from raw material to last-mile delivery. Powered by NEO, One Network’s machine learning and intelligent agent technology, it enables seamless planning and execution, across inbound supply, outbound order fulfillment, and logistics, matching demand with available supply in real-time. Lead your industry by providing the highest service levels and product quality at the lowest possible cost. Visit: www.onenetwork.com
About Blue Yonder
Blue Yonder is a world leader in digital supply chain transformation. Global retailers, manufacturers, and logistics providers leverage Blue Yonder to optimize their supply chains from planning through fulfillment, delivery, and returns. Blue Yonder’s AI-embedded, interoperable supply chain solutions are connected end-to-end via a unified platform and data cloud, enabling business to collaborate in real time across functions, which supports more agile decision-making, improved customer satisfaction, profitable growth, and more resilient, sustainable supply chains. Blue Yonder – Fulfill your Potential™ blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks, or service marks of the companies with which they are associated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328293246/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
